Results 1 to 10 of about 7,419 (143)

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial

EBioMedicine, 2015
Background: Abnormalities in membrane excitability and Na+ channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na+ channel blocker and membrane ...
Susanna B Park, Steve Vucic, Benjamin C Cheah   +2 more
exaly   +3 more sources

The Frontal QRS-T Angle Remains Unchanged in Patients Without Structural Heart Disease Receiving Flecainide Therapy [PDF]

Journal of Cardiovascular Development and Disease
Introduction: Prolongation of the QT interval and QRS duration, which are markers of ventricular repolarization and depolarization, has been reported in patients receiving flecainide therapy.
Mehmet Kucukosmanoglu, Mustafa Lutfullah Ardıc, Fadime Koca, Hilmi Erdem Sumbul, Mevlut Koc   +4 more
doaj   +2 more sources

Flecainide in Structural Heart Disease: Reconsidering Its Role in Contemporary Arrhythmia Management [PDF]

Life
Background: Flecainide has remained largely excluded from use in structural heart disease for more than three decades, mainly because of the Cardiac Arrhythmia Suppression Trial, which showed excess mortality in post-myocardial infarction patients ...
Paschalis Karakasis, Konstantinos Grigoriou, Panagiotis Theofilis, Panagiotis Iliakis, Panayotis K. Vlachakis, Nikolaos Ktenopoulos, Anastasios Apostolos, Dimitrios Patoulias, Antonios P. Antoniadis, Nikolaos Fragakis   +9 more
doaj   +2 more sources

Left atrial strain compared to volume in long-term flecainide treated patients with atrial fibrillation – a retrospective cohort study [PDF]

BMC Cardiovascular Disorders
Background Left atrial volume index (LAVI) is associated with recurrent atrial fibrillation (AF) during flecainide treatment. Nevertheless, AF patients with normal LAVI experience rhythm control failure.
Alexander Siotis, Pyotr G. Platonov, Bjarne Madsen Hardig   +2 more
doaj   +2 more sources

Reappraising Use of Flecainide for Atrial Fibrillation and Ventricular Arrhythmias in Structural Heart Disease Patients [PDF]

Medicina
Background: Flecainide, a class Ic antiarrhythmic agent, has long been contraindicated in structural heart disease (SHD) due to findings of the Cardiac Arrhythmia Suppression Trial (CAST).
Dimitrios Tsiachris, Sotirios C. Kotoulas, Ioannis Doundoulakis, Christos-Konstantinos Antoniou, Michail Botis, Konstantinos Pamporis, Nikolaos Argyriou, Aikaterini-Eleftheria Karanikola, Panagiotis Tsioufis, Athanasios Kordalis, Konstantinos Tsioufis   +10 more
doaj   +2 more sources

Flecainide‐Induced Interstitial Lung Disease: A Case Report and Review of the Literature [PDF]

Clinical Case Reports
This case describes a rare adverse effect in which the subject developed interstitial lung disease after initiating a class IC antiarrhythmic, flecainide.
Elizabeth Jenkins, John McGinty, Brian Skinner   +2 more
doaj   +2 more sources

Flecainide

Reactions Weekly
Arunachalam K, Patel P.
europepmc   +9 more sources

Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action

Cells, 2021
Cardiac ryanodine receptor (RyR2) mutations are implicated in the potentially fatal catecholaminergic polymorphic ventricular tachycardia (CPVT) and in atrial fibrillation.
Samantha C. Salvage, Esther M. Gallant, James A. Fraser, Christopher L.-H. Huang, Angela F. Dulhunty   +4 more
doaj   +1 more source

Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells

Frontiers in Pharmacology, 2023
Background and purpose: While flecainide is now an accepted treatment for arrhythmias associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), its mechanism of action remains controversial.
Emma J. Steer, Zhaokang Yang, Moza M. Al-Owais, Hannah M. Kirton, Edward White, Derek S. Steele   +5 more
doaj   +1 more source

Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia

Frontiers in Pediatrics, 2023
Flecainide is a class IC antiarrhythmic utilized in prophylaxis of refractory paroxysmal supraventricular tachycardias in pediatric populations. Despite being a highly effective agent, its narrow therapeutic index increases the risk of toxicity and ...
Ronald Palmen, Ronald Palmen, Ronald Palmen, Tracy Sandritter, Tracy Sandritter, Lindsey Malloy-Walton, Lindsey Malloy-Walton, Lindsey Malloy-Walton, Christopher Follansbee, Christopher Follansbee, Christopher Follansbee, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner   +15 more
doaj   +1 more source